Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Why hasn't neuroprotection worked in Parkinson's disease?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early PD. N Engl J Med 321: 1364–1371

  2. Palhagen S et al. (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200–1206

    Article  CAS  Google Scholar 

  3. Rascol O et al. (2002) A 2-year multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 17 (Suppl 5): S39

    Google Scholar 

  4. Shults CW et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541–1550

    Article  Google Scholar 

  5. Olanow CW et al. (2006) TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5: 1013–1020

    Article  CAS  Google Scholar 

  6. Shoulson I et al. (2006) CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study [abstract #S61.003]. Neurology 67: a185

    Article  Google Scholar 

  7. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of Rasagiline in early Parkinson disease. Arch Neurol 61: 561–566

  8. Ravina B et al. (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64: 208–215

    Article  CAS  Google Scholar 

  9. 9 NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664–671

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karl Kieburtz.

Ethics declarations

Competing interests

Karl Kieburtz has declared associations (support for research and/or consulting) with the following companies and organizations: Astellas Pharma US, Biogen Idec, Boehringer Ingelheim, Cephalon, the FDA, Medivation, Merz Pharmaceuticals, National Institutes of Health, Novartis Pharmaceuticals, Ortho-McNeil Neurologics, Prestwick Pharmaceuticals, Teva Pharmaceuticals and Vernalis.

Bernard Ravina has declared associations (support for research and/or consulting) with the following companies and organizations: Acadia, EnVivo, National Institutes of Health, Novartis, US Department of Defense, and Vernalis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kieburtz, K., Ravina, B. Why hasn't neuroprotection worked in Parkinson's disease?. Nat Rev Neurol 3, 240–241 (2007). https://doi.org/10.1038/ncpneuro0491

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0491

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing